Narrow Results

With the advancements in nanotechnology, the interaction between nanotechnology, society and environment has increased. Nanotherapeutics and nanopharmaceuticals have allowed facilitation of earlier and more precise diagnosis, reduced side effects, improved targeted therapies and efficacy of drugs. Likewise, nanotechnology has helped in improving the quality of environment by solving issues of air pollution, water remediation and waste management with the help of nanoproducts such as nanofilters, nanophoto catalysts, nanoadsorbents and nanosensors. Moreover, nanopesticides, nanofood, anti-bacterial nanopackaging, nanofertilizers and many other products have helped food and agriculture sector to grow. There are innumerable products on shelf based on nanotechnology impacting almost every sector. However, nanotechnology like any other technology if used unchecked and unregulated can be a cause of social, environmental, legal and ethical concerns. Therefore, it is crucial to consider these challenges in addition to the promises and opportunities nanotechnology has to offer. This review has highlighted the immense importance of nanotechnology by discussing its applications especially in medicine, environmental sciences and food and agriculture sectors. Closely studying these aspects will allow us to discover gaps, obstacles and potential solutions for responsible nanotechnology development and deployment. Understanding these concerns and challenges is also critical for policymakers, researchers, industrialists and society as a whole in order to promote ethical practices and informed decision-making. This review will help to contribute to the continuing discourse and raise ethical awareness in the field of nanotechnology thence minimizing the harm while maximizing the benefits.

With decreasing cost of biomedical technologies, the scale of the genetic and healthcare data have exponentially increased and become available to wider audiences. Hence, privacy of patients and study participants has garnered the attention of researchers and regulators alike. Availability of genetic and health care information for uses not anticipated at the time of collection gives rise to privacy concerns such that people suffer dignitary harm when their data is used in ways they did not desire or intend, even if no concrete economic damage results. In this workshop, we explore the issues surrounding data use to advance human health from a privacy perspective. Broadly this field can be considered in two encompassing areas: (1) Ethics and regulation of privacy: The ethical and regulatory frames through which we can consider privacy, the existing regulations regarding privacy and what is on the horizon, and implementation of such ethical considerations for data with the new Common Rule. (2) Approaches to ensuring privacy using technology: The technologies that allow responsible use and sharing of data such as encryption and the quantification of privacy leakages in publicly available data through privacy attacks for better risk-assessment tools.

Innovations in human-centered biomedical informatics are often developed with the eventual goal of real-world translation. While biomedical research questions are usually answered in terms of how a method performs in a particular context, we argue that it is equally important to consider and formally evaluate the ethical implications of informatics solutions. Several new research paradigms have arisen as a result of the consideration of ethical issues, including but not limited for privacy-preserving computation and fair machine learning. In the spirit of the Pacific Symposium on Biocomputing, we discuss broad and fundamental principles of ethical biomedical informatics in terms of Olelo Noeau, or Hawaiian proverbs and poetical sayings that capture Hawaiian values. While we emphasize issues related to privacy and fairness in particular, there are a multitude of facets to ethical biomedical informatics that can benefit from a critical analysis grounded in ethics.

Machine learning predictive analytics (MLPA) are utilized increasingly in health care, but can pose harms to patients, clinicians, health systems, and the public. The dynamic nature of this technology creates unique challenges to evaluating safety and efficacy and minimizing harms. In response, regulators have proposed an approach that would shift more responsibility to MLPA developers for mitigating potential harms. To be effective, this approach requires MLPA developers to recognize, accept, and act on responsibility for mitigating harms. In interviews of 40 MLPA developers of health care applications in the United States, we found that a subset of ML developers made statements reflecting moral disengagement, representing several different potential rationales that could create distance between personal accountability and harms. However, we also found a different subset of ML developers who expressed recognition of their role in creating potential hazards, the moral weight of their design decisions, and a sense of responsibility for mitigating harms. We also found evidence of moral conflict and uncertainty about responsibility for averting harms as an individual developer working in a company. These findings suggest possible facilitators and barriers to the development of ethical ML that could act through encouragement of moral engagement or discouragement of moral disengagement. Regulatory approaches that depend on the ability of ML developers to recognize, accept, and act on responsibility for mitigating harms might have limited success without education and guidance for ML developers about the extent of their responsibilities and how to implement them.

Large Language Models (LLMs) are a type of artificial intelligence that has been revolutionizing various fields, including biomedicine. They have the capability to process and analyze large amounts of data, understand natural language, and generate new content, making them highly desirable in many biomedical applications and beyond. In this workshop, we aim to introduce the attendees to an in-depth understanding of the rise of LLMs in biomedicine, and how they are being used to drive innovation and improve outcomes in the field, along with associated challenges and pitfalls.

Large language models (LLMs) and biomedical annotations have a symbiotic relationship. LLMs rely on high-quality annotations for training and/or fine-tuning for specific biomedical tasks. These annotations are traditionally generated through expensive and time-consuming human curation. Meanwhile LLMs can also be used to accelerate the process of curation, thus simplifying the process, and potentially creating a virtuous feedback loop. However, their use also introduces new limitations and risks, which are as important to consider as the opportunities they offer. In this workshop, we will review the process that has led to the current rise of LLMs in several fields, and in particular in biomedicine, and discuss specifically the opportunities and pitfalls when they are applied to biomedical annotation and curation.